InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$428.26

2026-10-16

Market Cap

$92.9B

Volume

1.2M

52-Wk High

$436.24

52-Wk Low

$273.71

Trailing PE

19.0

P/S

0.46

Gross Margin

39.0%

Net Margin

2.5%

ROE

11%

ROIC

6%

Piotroski

8/9

Altman Z

3.2

1-Yr Return

+23.6%

5-Yr Return

+75.2%

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

SectorHealthcareIndustryMedical - Healthcare PlansExchangeNYSEMarket Cap$92.9BEmployees97,100 (SEC-filed)CEOGail Koziara BoudreauxIPO2001-10-30CountryUS

220 Virginia Avenue, Indianapolis, IN 46204 · Tel 800 331 1476 · elevancehealth.com

INSIDERSTREET SCORE57 / 100Street mean $464.50 (2 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALNET BUYING$2.2M open-market purchases vs $1.7M sales / 6 mo

INSIDERSTREET
SCORE57of 100

Score Breakdown

Profitability	38/100
Growth	39/100
Momentum	69/100
Quality	69/100
Earnings Quality	84/100
Balance Sheet	76/100
Value	68/100
Risk (safety)	80/100
Overall	57.0/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
CI	61
CVS	52
HUM	27
CNC	37
UNH	51
MOH	30
ELV	57

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 65 in 23 Q2, latest 57 — -8 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

1 Year vs S&P 500 · ELV +23.6% · S&P 500 +15.9% · spread +7.7pp

7 Years vs S&P 500 · ELV +75.2% · S&P 500 +189.9% · spread -114.7pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

BUSINESS QUALITY57 / 100IS Score 57.0 / 100 · -7.9 from peak of 65

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 86 / 100 · Power +73 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 57 and price structure at 86 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 57.0	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 44 → 39 → 52 → 57	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)3$1.37M

ETF Funds (30d)467 up / 443 downnet +24 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Kaye Mark	EVP & CFO	2026-10-02	TAX W/H	4,161	$1.61M	27,876
Kaye Mark	EVP & CFO	2026-10-02	A-Award	2,627	—	30,503
Wessling Erin M	EVP & Chief Legal Officer	2026-09-03	TAX W/H	255	$0.11M	7,230
Wessling Erin M	EVP & Chief Legal Officer	2026-09-02	TAX W/H	94	$0.04M	7,485
Craig Ryan R	EVP & Chief HR Officer	2026-09-02	TAX W/H	144	$0.06M	6,530
Boudreaux Gail	director, President and CEO	2026-07-17	BUY	680	$0.25M	169,931
Boudreaux Gail	director, President and CEO	2026-07-17	BUY	2,045	$0.75M	171,976
Peru Ramiro G	director	2026-07-17	BUY	1,000	$0.37M	10,908

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	5	5,273	$1.7M	Counted
P — Open-market purchases	4	6,725	$2.2M	Counted
M — Exercises (paired A/D)	2	1,531	$0.5M	None — mechanics
F — Tax withholding	21	20,425	$6.4M	None — compensation

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalNet Buying

Open-Market Sells$1.7M5 txns / 6 mo

Open-Market Buys$2.2M4 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-07-07	Clark R Kerry	1,500	$0.6M
2026-06-12	Ronald William Penczek	369	$0.1M
2026-06-11	Dixon Robert L Jr	151	$0.1M
2026-05-19	Ronald William Penczek	1,531	$0.6M
Trailing 12 mo	5 filings	6,747	$2M

Filed	Form	Reporting person	% of class	Shares
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.13%	16.6M sh
2025-05-07	SCHEDULE 13G/A	The Vanguard Group	10.13%	22.9M sh
2025-04-17	SCHEDULE 13G/A	BlackRock, Inc.	7.80%	17.7M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-01-29	2026-02-10
Ro Khanna	House	BUY	$1,001 - $15,000	2025-09-29	2025-10-03
Ro Khanna	House	BUY	$1,001 - $15,000	2025-09-05	2025-10-03
Markwayne Mullin	Senate	BUY	$15,001 - $50,000	2025-12-29	2026-01-16
Markwayne Mullin	Senate	BUY	$15,001 - $50,000	2025-12-29	2026-01-15
John Fetterman	Senate	SELL	$1,001 - $15,000	2025-09-19	2025-10-07

House 12-Mo4 trades3 purchases

Senate 12-Mo4 trades2 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,602

13F Shares199M90.0% of shares out

New / Closed110 / 1199positions, QoQ

Increased / Reduced637 / 600positions, QoQ

Put/Call (13F)0.86option positions

Free Float99.8%216M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Ninety One Uk Ltd	472,922	$184M
Davenport & Co Llc	384,435	$150M
Assenagon Asset Management S.A.	152,374	$59M
Fjarde Ap-Fonden /Fourth Swedish N	95,165	$37M
Zwj Investment Counsel Inc	93,029	$36M
Gateway Investment Advisers Llc	78,142	$30M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$2.6B
VTSAX	0.1%	$2.6B
VTI	0.1%	$2.6B
VSMPX	0.1%	$2.6B
VFINX	0.1%	$2.2B
VFIAX	0.1%	$2.2B

13F Filers Holding ELV — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session36.1%2026-10-15

20-Day Avg52.4%50-day 56.3%

TrendFalling20d vs 50d

By Market CenterQ: 36% · N: 33% · B: 22%latest session

Weekly Notional ($B)

Where ELV Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	2.0M	27 sh
Ubsa Ubs Ats	1.6M	32 sh
Ebxl Level Ats	1.2M	23 sh
Sgmt Sigma X2	1.0M	25 sh
Mlix Instinct X	0.8M	38 sh
Mspl Ms Pool (Ats-4)	0.7M	73 sh

Where a dollar of Elevance Health Inc. revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

ELV (live moat model)Peer median: CI · CVS · HUM · CNC · UNH

Component scores from the live moat model. Peer median illustrative.

Moat score 52/100 — Weak; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Gail Koziara Boudreaux	President, Chief Executive Officer & Director
Peter David Haytaian	Special Advisor
Felicia Farr Norwood	Executive VP & Chief Health Benefits Officer
Mark Bradley Kaye	Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+11.7%

Next Report2026-10-21

Income Quality1.51OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+13.8%	+13.0%	+9.4%	+3.2%	+12.6%
Gross profit	+13.8%	+13.0%	+9.4%	+3.2%	-71.2%
Operating income	+28.2%	-4.9%	+1.5%	+2.4%	+2.6%
Net income	+34.7%	-4.3%	+1.6%	-0.1%	-5.3%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	138.6	156.6	171.3	176.8	199.1
Cost of revenue	0.0	0.0	0.0	0.0	148.2
Gross profit	138.6	156.6	171.3	176.8	50.9
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	15.9	17.7	0.0	0.0	0.0
Operating income	8.0	7.6	7.7	7.9	8.1
EBITDA	10.1	10.1	10.5	10.5	9.7
D&A	1.3	1.7	1.7	1.4	1.5
Pretax income	8.0	7.6	7.7	7.9	6.7
Income tax	1.8	1.7	1.7	1.9	1.0
Net income	6.2	5.9	6.0	6.0	5.7
Diluted EPS ($)	24.73	24.28	25.22	25.68	25.12
Diluted shares (M)	247	243	237	233	222

Operating CF$4B

CapEx$1B

Free cash flow$3B

SBC$0B

Buybacks$3B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	7.4	6.5	8.3	9.5
ST investments	26.0	29.6	25.2	0.0
Receivables (net)	16.0	17.9	19.1	15.2
Total current assets	0.0	0.0	0.0	24.7
PP&E (net)	4.3	4.4	4.7	5.1
Goodwill + intangibles	34.7	35.6	40.4	39.5
Total assets	102.8	108.9	116.9	121.5
Accounts payable	21.2	23.0	22.7	17.1
Short-term debt	1.8	1.9	2.0	1.4
Deferred revenue	1.1	1.4	1.5	1.5
Total current liabilities	0.0	0.0	0.0	20.0
Long-term debt	22.3	23.2	29.2	31.3
Total liabilities	66.4	69.5	75.5	77.5
Shareholders' equity	36.3	39.4	41.4	44.0

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	6.0	6.0	6.0	5.7
D&A	1.7	1.7	1.4	1.5
Stock-based compensation	0.3	0.3	0.2	0.3
Working capital change	0.3	(0.5)	(1.7)	(3.3)
Operating cash flow	8.4	8.1	5.8	4.3
Capital expenditures	(1.2)	(1.3)	(1.3)	(1.1)
Investing cash flow	(4.6)	(5.6)	(5.2)	(1.3)
Buybacks	(2.3)	(2.7)	(2.9)	(2.6)
Dividends paid	(1.2)	(1.4)	(1.5)	(1.5)
Debt issuance / (repay)	1.8	0.7	5.6	2.3
Financing cash flow	(1.3)	(3.3)	1.2	(1.7)
Free cash flow	7.2	6.8	4.6	3.2

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	17.6%	16.5%	15.8%	14.8%	13.3%	11%
ROA	6.6%	6.0%	5.7%	5.3%	4.8%	3.9%
ROIC	21.8%	22.1%	21.2%	15.3%	9.3%	6.3%
Gross margin	100.0%	100.0%	100.0%	100.0%	25.6%	39.0%
Operating margin	5.8%	4.9%	4.5%	4.5%	4.1%	3.5%
Net margin	4.4%	3.8%	3.5%	3.4%	2.8%	2.5%
EBITDA margin	7.3%	6.5%	6.1%	5.9%	4.9%	4.2%
FCF margin	5.2%	4.6%	3.9%	2.6%	1.6%	—
VALUATION
P/E	17.63	19.78	17.98	13.99	13.73	19.0
P/B	2.98	3.26	2.74	2.02	1.77	2.1
P/S	0.78	0.76	0.63	0.47	0.39	0.46
P/FCF	14.79	16.32	15.91	18.37	24.50	14.8
EV/EBITDA	9.93	10.65	9.21	7.76	10.51	13.4
EV/Revenue	0.72	0.70	0.56	0.46	0.51	0.6
Earnings yield	5.7%	5.1%	5.6%	7.2%	7.3%	5.32%
FCF yield	6.8%	6.1%	6.3%	5.4%	4.1%	6.77%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	—	—	—	—	1.24	2.05
Quick ratio	—	—	—	—	1.24	2.05
Debt / equity	0.64	0.67	0.64	0.76	0.76	0.69
Debt / assets	23.6%	23.5%	23.1%	26.7%	27.4%	24.6%
Net debt / EBITDA	-0.81	-0.90	-1.05	-0.22	2.46	2.45
Interest coverage	10.93	10.06	8.49	7.67	5.79	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	1.51	1.56	1.62	1.57	1.67	1.59
Receivables turnover	25.30	24.54	22.87	22.22	17.13	8.6
DSO (days)	14	15	16	16	21	42
DPO (days)	—	—	—	—	95	75
Cash conversion cycle	—	—	—	—	-74	-32
GROWTH (YoY)
Revenue growth	13.8%	13.0%	9.4%	3.2%	12.6%	—
Net income growth	33.5%	-2.1%	0.2%	-0.1%	-5.3%	—
EPS growth	36.6%	-0.3%	2.4%	1.9%	-1.3%	—
FCF growth	-24.7%	-0.4%	-6.7%	-32.7%	-30.3%	—
PER SHARE ($)
EPS (diluted, TTM)	24.86	24.78	25.39	25.88	25.53	22.78
Book value / share	146.88	150.26	166.69	178.78	197.84	206.62
Revenue / share	564.72	649.23	726.63	765.08	897.77	922.96
FCF / share	29.64	30.05	28.69	19.70	14.31	28.86
Cash / share	126.87	138.22	153.27	144.91	42.79	172.16
SHAREHOLDER RETURN & SCORES
Buyback yield	1.8%	2.0%	2.5%	3.5%	3.4%	3.21%
Altman Z-Score	3.16	3.27	3.17	2.84	2.92	3.2
Piotroski F-Score	6	6	6	3	4	8/9
Beneish M-Score	-2.33	-2.40	-2.28	-2.39	-0.95	-2.71

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	3.2	Safe (>2.99)	Safe
Income quality	1.51	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.71	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.85
Interest burden	0.84
Operating margin	3.5%
Asset turnover	1.62×
Financial leverage	2.80×
= ROE	11%

Growth Quality (live)	Value
Revenue stability	0.98
Earnings stability	0.01
Earnings persistence	0.97
Revenue CAGR 3y	6.7%
EPS CAGR 3y	-5.4%
FCF CAGR 3y	-15.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield3.21%

Dividend Yield1.60%

Total Shareholder Return4.93%cash yield

SBC / Revenue0.1%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
CI	$79.9B	12.5	15%	2.3%	+7.7%	8/9	+4.5%
CVS	$118.1B	24.1	6%	2.8%	+7.4%	8/9	+14.4%
HUM	$49.6B	38.8	7%	1.7%	+18.3%	4/9	+54.6%
CNC	$34.2B	-6.7	-20%	2.5%	+8.7%	6/9	+94.0%
UNH	$360.3B	22.9	16%	3.6%	+3.3%	7/9	—
MOH	$10.8B	1296.0	-0%	0.6%	+2.6%	5/9	—
MRNA	$87.0B	-27.3	-39%	—	-27.2%	2/9	—
HCA	$99.3B	15.3	-125%	8.4%	+7.3%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

38 Analysts

Str Sell (0)Sell (0)Hold (11)Buy (27)Str Buy (0)

Mean Target (qtr)$464.502 targets

Target vs. Price+8.5%last-quarter mean

Next Report2026-10-21street $4.70

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$197.08B	$201.66B / $191.68B	$27.24	$28.22 / $27.02	13
FY2027	$201.45B	$213.88B / $194.12B	$29.63	$30.51 / $29.01	13
FY2028	$211.93B	$220.75B / $198.93B	$33.99	$36.63 / $32.14	4

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$464.50	+8.5%	2
Last Quarter	$464.50	+8.5%	2
Last Year	$418.78	-2.2%	50
All Time	$469.75	+9.7%	102

Rolling mean of published targets vs. last close $428.26. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

5/5

ROE

3/5

ROA

4/5

Debt/Eq

1/5

P/E

3/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

ELV +23.6% vs S&P 500 +15.9% — spread +7.7pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$404.67	+23.59	+5.83%	Above
SMA 50	$403.53	+24.73	+6.13%	Above
SMA 200	$368.96	+59.30	+16.07%	Above
EMA 9	$418.30	+9.96	+2.38%	Above
EMA 21	$410.22	+18.04	+4.40%	Above
EMA 50	$403.78	+24.48	+6.06%	Above
EMA 200	$379.93	+48.33	+12.72%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7320 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%91

Volume 20%81

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago18%+82 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$404.67

Price vs SMA 50$403.53

Price vs SMA 200$368.96

EMA 9/21 Cross418.3/410.2

SMA 50/200Golden

ADX DirectionADX 20

Supertrend$400

Parabolic SAR$400

SMA Slope0.850

RSI66.8

Stochastic K/D90/90

StochRSI K/D100/100

Williams %R-10

CCI138

TSI vs Signal18.6

CMO33.6

ROC10.76%

OBV SignalAccum

Chaikin MF-0.060

MFI77

Force Index4M

Elder Ray Bull23.77

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 90

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$428.52 / $432.17 / $435.91	S1 / S2	$424.78 / $421.13
Bollinger (20,2)	$375.95 – $433.39	Squeeze	Off
52-wk range	$273.16 – $436.24	Off 52-wk high	-1.9%
ATR (14)	$10.26 (2.4%)	Historical vol	20.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+0.8%Jan50%

-1.7%Feb45%

+2.3%Mar62%

+2.2%Apr55%

+2.2%May65%

-0.8%Jun40%

-1.5%Jul55%

+1.4%Aug55%

-1.3%Sep40%

+1.6%Oct55%

+4.0%Nov70%

+2.1%Dec55%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	ELV	S&P 500
Weekly volatility (σ, 1y)	4.52%	1.83%
Best / worst week (1y)	+8.6% / -11.3%	—
Max drawdown (5y, monthly)	-46.8%	—
1-week VaR (95%)	-7.7%	—
Beta (5y)	0.70	1.00

ELV EQUITY WEATHER (LIVE)PARTLY CLOUDY · +24

Trend+44

Momentum+67

Volume+28

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 257 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+23.8+14.7 vs industry

Trend+44.3+5.3 vs industry

Momentum+67.4+11.4 vs industry

Volume+28.3+3.8 vs industry

Reading	ELV	Medical - Healthcare Plans n=28	Healthcare n=5,272	All US symbols n=70,435
Overall	+23.8	+9.1	-24.0	-20.5
Trend	+44.3	+39.0	-25.6	-21.3
Momentum	+67.4	+56.0	-28.5	-15.8
Volume	+28.3	+24.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Larry C. Glasscock Chairman of the Board, Pr	$8.9M	36% equity+incentive
David C. Colby Executive Vice President and	$3.7M	28% equity+incentive
Keith R. Faller President and CEO Central Re	$3.4M	30% equity+incentive
Joan E. Herman President and CEO Specialty,	$2.7M	29% equity+incentive
John S. Watts, Jr. President and CEO Nationa	$2.5M	31% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	55
Social	57
Governance	55
Composite ESG	56

Composite ESG Trend

Filed	8-K contents	Items
2026-09-10	Regulation FD	7.01
2026-07-15	Earnings Release; Exhibits	2.02,9.01
2026-06-10	Regulation FD	7.01
2026-05-13	Shareholder Vote	5.07
2026-04-22	Earnings Release; Exhibits	2.02,9.01
2026-03-10	Regulation FD Disclosure	7.01
2026-03-02	Other Events	8.01
2026-02-26	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-07-29 to 2026-04-22
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	45 rows · 2014 to 2025
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-05-19 to 2026-10-02
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	3 rows · 2025-04-17 to 2026-04-29
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Elevance Health Inc. (ELV)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Monthly Net Insider Flow (000 shares)

Signal Summary

Elevance Health Inc. (ELV)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding ELV — quarterly

Institutional Put/Call — quarterly

Elevance Health Inc. (ELV)

Where ELV Trades in the Dark

Elevance Health Inc. (ELV)

3.8 · Employees (SEC filings)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Balance Sheet — Full

Cash Flow Statement — Full

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Street Price Target — Trajectory

Third-Party Composite Rating

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Family Scores (site weights)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)

Elevance Health Inc. (ELV)